Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Yael L. Maxwell

March 01, 2022

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

Advertisement

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

OMT Boosts Survival in Revascularized Patients at 10 Years

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Recurrent Events Common Among Young Patients With CAD

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content